Immuneering to Participate in Jefferies 2021 London Healthcare Conference
10 nov. 2021 06h50 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights
09 nov. 2021 06h30 HE
|
Immuneering Corporation
Successfully completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024 Company expects to file IND for IMM-1-104 in Q1 2022 CAMBRIDGE, Mass.,...
Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
11 oct. 2021 06h50 HE
|
Immuneering Corporation
Preclinical Data Demonstrated Broad Antitumor Activity Across KRAS, NRAS and BRAF Mutant Tumor Models, Established Novel Mechanism of Action for its Dual MEK Inhibition and Showed Synergies with...
Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
01 oct. 2021 06h50 HE
|
Immuneering Corporation
Preclinical Data Demonstrates Broad Antitumor Activity of IMM-1-104 Across RAS and RAF Mutant Tumors and Highlights Mechanistic Aspects of its Dual MEK Inhibition Company to Host Key Opinion Leader...
Immuneering Announces Inclusion in the Russell 2000® Index
20 sept. 2021 16h10 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates
09 sept. 2021 06h30 HE
|
Immuneering Corporation
Recently completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024 Company expects to file IND for IMM-1-104 in Q1 2022 CAMBRIDGE, Mass.,...
Immuneering to Participate in September Investor Conferences
02 sept. 2021 16h05 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
03 août 2021 16h07 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Announces Pricing of Upsized Initial Public Offering
29 juil. 2021 22h48 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Appoints Michael Bookman as General Counsel and Secretary
20 juil. 2021 06h47 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (“Immuneering”), a private biopharmaceutical company advancing a robust pipeline of oncology and neuroscience drug...